Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCUS: 3 vs 6 Cycles of Chemotherapy Prior to Avelumab in Advanced Urothelial Cancer
NCT06892860Phase 2Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Dec 2021
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of avelumab, gemcitabine, cisplatin, carboplatin in urothelial carcinoma (UC), sponsored by Queen Mary University of London. Started Dec 2021; status: recruiting.
02
Drugs
avelumabgemcitabinecisplatincarboplatin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06892860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892860.